Glucagon Receptor Activation: In-Depth Analysis of Research Data
Title: Glucagon Receptor Activation: In-Depth Analysis of Research Data Abstract: Activation of glucagon receptor (GCGR) drives hepatic glucose production and lipid metabolism, with research data showing 30–50% efficacy in type 2 diabetes models. Current market trends favor dual agonists (e.g., GLP-1/GCGR) over mono-target peptides, with brands like Novo Nordisk and Eli Lilly leading Phase II/III trials. Technical advantages include enhanced glycemic control and weight loss; disadvantages involve hyperglycemia risk at high doses. Product comparisons highlight purity (>98% HPLC) and stability (lyophilized vs. liquid). Applications span diabetes, NASH, and obesity. Industry growth is projected at 12% CAGR (2024–2030), driven by regulatory approvals and manufacturing scalability.